How to Sell a Medical Practice: The 2026 Physician’s Guide to Multiples, Buyers, and Process

Christoph Totter · Managing Partner, CT Acquisitions

20+ home services M&A transactions across HVAC, plumbing, pest control, roofing · Updated May 19, 2026

Selling a medical practice is one of the most regulatory-complex small-business sale processes. Beyond standard M&A diligence, sellers must navigate Stark Law (physician self-referral prohibitions), Anti-Kickback Statute, state licensure transfer (which can take 6-12 months in some states), Medicare/Medicaid provider agreement transfer, malpractice tail coverage requirements, and patient-record HIPAA considerations. The process is rewarding (multiples reach 8-12x EBITDA for in-demand specialties) but demands physician-experienced advisors.

This guide covers the practical sale process: 2026 valuations by specialty, buyer types (PE-backed physician groups, hospital systems, larger practices), regulatory considerations, 12-month preparation playbook, and post-close transition expectations. Physician practices have become a major PE roll-up sector since 2018, with active platforms in dermatology, ophthalmology, gastroenterology, orthopedics, dental, vet, and more. For physician-owners considering sale, the path to maximizing value requires understanding both the medical practice fundamentals and the PE-buyer playbook.

Medical practice founder reviewing sale documents at executive desk, with practice valuation report visible, brass desk lamp casting warm golden light, polished walnut surface
Selling a medical practice in 2026 produces 4-8x EBITDA for most specialties; PE-backed physician group acquisitions can reach 10-12x. The process is regulated, complex, and rewards thorough preparation.

“Selling a medical practice in 2026 is fundamentally different from selling any other small business. The regulatory complexity alone adds 30-50% to the typical process timeline — but the multiples PE pays for the right specialties make the work worth it.”

TL;DR — the 90-second brief

  • Medical practices sell at 4-8x EBITDA in 2026 for most specialties; PE-backed physician group acquisitions reach 8-12x for high-demand specialties.
  • Three primary buyer types: PE-backed physician groups (dermatology, ophthalmology, gastroenterology, dental, vet), hospital systems, larger practices/groups.
  • Regulatory complexity is substantial: Stark Law, Anti-Kickback Statute, state licensure transfer, Medicare/Medicaid provider agreements, malpractice tail coverage.
  • Preparation 12+ months in advance produces 20-40% higher net proceeds: optimize provider productivity, document referral patterns, address staff retention, audit billing compliance.
  • CT Acquisitions works with PE-backed physician groups actively acquiring practices. The buyer pays our fee at close — the seller pays nothing.

Key Takeaways

  • Medical practice multiples 2026: 4-8x EBITDA most specialties; 8-12x for PE-favored high-demand specialties.
  • Three buyer types: PE-backed physician groups (most active), hospital systems, larger practices/groups.
  • Active PE roll-up specialties: dermatology, ophthalmology, gastroenterology, orthopedics, dental, vet, plastic surgery, pain management.
  • Regulatory complexity: Stark Law, Anti-Kickback, state licensure transfer, Medicare/Medicaid provider agreements, HIPAA, malpractice tail.
  • Preparation 12+ months pre-sale produces 20-40% higher proceeds: optimize productivity, document referral patterns, address staff retention.
  • Process timeline: 9-18 months from advisor engagement to close (longer than standard M&A due to regulatory work).
  • Post-close: physicians typically remain 3-5+ years as employed providers + equity holders in the platform.
  • Critical valuation drivers: payor mix, provider productivity, referral patterns, ancillary revenue (in-office surgery, imaging, lab), real estate ownership.

Medical practice valuation: 2026 multiples by specialty

Multiples vary widely by specialty. Below are 2026 typical ranges for healthy, growing practices being acquired by PE-backed physician groups or larger practices.

Specialty Typical EBITDA Multiple PE Roll-Up Active?
Dermatology 8-12x Yes — highly competitive (DermCare, Forefront, Schweiger)
Ophthalmology 8-11x Yes — EyeCare Partners, MyEyeDr., Acuity
Gastroenterology 7-10x Yes — GI Alliance, US Digestive Health, One GI
Orthopedics 7-10x Growing — US Orthopedic Partners, Healthcare Outcomes Performance
Dental (DSO) 6-9x Yes — Heartland, Aspen, Pacific Dental, Smile Brands
Plastic surgery 6-9x Growing — Schweiger, Eos Surgical
Pain management 6-9x Yes — National Spine & Pain, Pain Treatment Centers
Veterinary 8-15x Highest multiples — Mars/Banfield, NVA, BluePearl
Primary care 4-6x Limited — Oak Street, Iora (consolidating), Privia
OB/GYN 5-7x Growing — Axia, Women’s Health Texas
ENT 5-7x Growing — ENT Specialty Partners
Urology 5-7x Growing — US Urology Partners, Solaris
Cardiology 4-7x Limited — most stayed at hospital systems
Psychiatry/Behavioral health 6-10x Growing — Refresh Mental Health, LifeStance
Buyer type Cash at close Rollover equity Exclusivity Best fit for
Strategic acquirer High (40–60%+) Low (0–10%) 60–90 days Sellers who want a clean exit; competitor or upstream consolidator
PE platform Medium (60–80%) Medium (15–25%) 60–120 days Sellers willing to hold rollover for the second sale; bigger deals
PE add-on Higher (70–85%) Low–Medium (10–20%) 45–90 days Sellers folding into existing platform; faster process
Search fund / ETA Medium (50–70%) High (20–40%) 90–180 days Legacy-conscious sellers wanting an owner-operator successor
Independent sponsor Medium (55–75%) Medium (15–30%) 60–120 days Sellers OK with deal-by-deal capital and longer financing closes
Different buyer types structure LOIs differently because their economics differ. A search fund’s earnout-heavy 50% cash deal looks worse than a strategic’s 60% cash deal—but the search fund’s rollover often pays back at multiples in 5-7 years.

Three primary buyer types

Medical practice sales typically go to one of three buyer types. Each has different process, valuations, and post-close physician expectations.

1. PE-backed physician groups

PE-backed physician groups are the dominant buyer for in-demand specialties. Strategy: acquire platform practice ($5-25M EBITDA), bolt on smaller practices over 3-5 years, exit to larger PE or strategic at higher multiple. Valuations: 8-12x for first add-ons in a new region; 6-8x for later add-ons in saturated regions. Post-close: physician typically becomes W-2 employee of platform + holds 10-20% equity in platform (tax-deferred via rollover).

2. Hospital systems

Hospital systems acquire practices for service-line expansion and referral capture. Valuations: 3-6x EBITDA typically (below PE because hospital systems can’t apply PE-scale operational improvements). Post-close: physician typically becomes hospital-employed; loses owner autonomy and equity upside. Better for specialties without active PE consolidation (cardiology, primary care historically).

3. Larger practices and groups

Independent larger practices and groups acquire smaller competitors for geographic expansion and ancillary revenue. Valuations: 4-7x EBITDA. Less institutional process; often negotiated bilateral deals. Post-close: physician integrates into existing group; potentially equity partnership if group is partnership-structured.

Considering selling your medical practice?

CT Acquisitions works with PE-backed physician groups actively acquiring practices in dermatology, ophthalmology, GI, orthopedics, dental, vet, and more. The buyer pays our fee at close — the seller pays nothing.

Book a 30-Min Call

Regulatory complexity: what makes medical sales different

Medical practice sales involve regulatory considerations that don’t exist in other industries. These add 6-12 months to the typical sale timeline and require physician-experienced legal counsel.

  • Stark Law (Self-Referral Prohibition). Physicians can’t refer Medicare/Medicaid patients to entities with which they have a financial relationship. Sale structures must comply with safe harbors.
  • Anti-Kickback Statute. Prohibits remuneration for healthcare referrals. Deal structure (especially earnouts tied to referrals) needs careful review.
  • State Licensure Transfer. Many states require provider re-credentialing under new ownership (6-12 months in some states; weeks in others).
  • Medicare/Medicaid Provider Agreements. Transfer requires CMS approval; typically 3-9 months.
  • HIPAA and Patient Records. Patient consent often required for record transfer; complex for large practices with thousands of patients.
  • Malpractice Tail Coverage. Selling physician must obtain ‘tail’ coverage for claims arising from pre-close activities ($25K-$200K typical cost).
  • Contract Assignability. Insurance contracts, lease agreements, vendor agreements often have change-of-control restrictions.
  • Antitrust review. Larger deals ($101M+ HSR threshold) require FTC notification. Some specialty markets have anti-consolidation pressure.

Valuation drivers: what moves multiples up

Six factors move medical practice multiples within their specialty range. Optimizing these 12-24 months pre-sale produces 20-40% higher valuation.

  1. Payor mix. Commercial payors (BCBS, UHC, Aetna, Cigna) command higher rates than Medicare/Medicaid. Practices with 60%+ commercial mix get premium multiples.
  2. Provider productivity. Production per provider (collections, RVUs, patient volume) above specialty median commands premium.
  3. Referral patterns. Stable inbound referral relationships from PCPs, specialists, hospitals. Document these clearly for buyer diligence.
  4. Ancillary revenue. In-office surgery, imaging (PET, MRI, ultrasound), lab work, infusion services, pharmacy. Each ancillary stream adds material EBITDA and multiple.
  5. Real estate ownership. Physician-owned real estate often sold separately (sale-leaseback) for additional value beyond practice EBITDA.
  6. Provider depth. 3+ providers reduces key-person risk; 5+ providers attracts PE platforms; single-provider practices command lower multiples.

Pre-sale preparation: 12-month playbook

Preparation 12+ months in advance materially improves outcomes. Below is the canonical timeline.

  1. 12-18 months out: Engage healthcare-experienced M&A advisor for valuation benchmark. Optimize payor mix (drop low-paying contracts). Address provider productivity gaps. Document referral patterns systematically.
  2. 9-12 months out: Clean up financials (GAAP-compliant, monthly close discipline). Implement clean Chart of Accounts separating practice income from owner-discretionary expenses. Address pending litigation or regulatory issues.
  3. 6-9 months out: Engage healthcare M&A attorney for regulatory pre-clearance. Document staff retention strategy. Sell-side QoE for $5M+ EBITDA practices.
  4. 3-6 months out: Marketing teaser/CIM preparation. Initial buyer outreach to PE platforms and larger practices.
  5. 3-0 months out: LOI process. Diligence support. Regulatory pre-filing where applicable.
  6. Post-LOI to close: Full due diligence (90-150 days for medical; longer than standard M&A). State licensure work. CMS provider transfer.
Component Typical share of price When you actually receive it Risk to seller
Cash at close 60–80% Wire on closing day Low — this is real money
Earnout 10–20% Over 18–24 months, performance-based High — routinely paid out at less than face value
Rollover equity 0–25% At the next platform sale (typically 4–6 years) Variable — can multiply or go to zero
Indemnity escrow 5–12% 12–24 months after close (if no claims) Medium — usually returned, sometimes contested
Working capital peg +/- 2–7% of price Adjustment at close or 30-90 days post High — methodology disputes are common
The headline LOI number is rarely what hits your bank account. Cash-at-close is the only line that lands the day of close; everything else carries timing or performance risk.

Post-close: what physicians can expect

Post-close physician role varies dramatically by buyer type. Understanding the post-close path is critical for choosing the right buyer.

Buyer Type Physician Role Post-Close Compensation Structure
PE-backed group W-2 employee + platform equity (10-20% rollover) Base salary + production bonus + equity vesting
Hospital system W-2 employee Base salary + production bonus (RVU-based typical)
Larger practice Employed or partner depending on group structure Salary or partner draw
MSO (Management Services Organization) Independent contractor with management agreement Variable based on MSO structure

Specialties most attractive to PE in 2026

Five specialty categories have strongest PE consolidation activity in 2026. Sellers in these specialties enjoy multiple competing platforms and premium valuations.

  • Dermatology. 5+ active platforms (DermCare Management, Forefront Dermatology, Schweiger Dermatology Group, Pinnacle Dermatology, others). 8-12x EBITDA typical.
  • Ophthalmology. EyeCare Partners, MyEyeDr., Acuity Eyecare Group. Optometry consolidation also active.
  • Gastroenterology. GI Alliance, US Digestive Health, One GI. ASC ownership critical to valuations.
  • Dental DSOs. Heartland Dental, Aspen Dental, Pacific Dental Services, Smile Brands. Mature market; multiples 5-9x.
  • Veterinary. Highest multiples (8-15x EBITDA). Mars/Banfield, NVA, BluePearl, VCA dominate.

Pricing your practice: realistic expectations

For a typical 3-provider specialty practice at $3M EBITDA, here’s the practical pricing range by specialty. Use as benchmark; specific deals vary based on geography, payor mix, ancillary revenue.

Specialty Profile Multiple Range Implied EV
Dermatology, 3 providers, $3M EBITDA, strong commercial mix 9-12x $27M-$36M
Ophthalmology, 3 providers, $3M EBITDA, ASC ownership 8-11x $24M-$33M
GI, 3 providers, $3M EBITDA, ASC ownership 8-11x $24M-$33M
Orthopedics, 3 providers, $3M EBITDA, surgery-heavy 7-10x $21M-$30M
Dental, 3 dentists, $3M EBITDA 6-9x $18M-$27M
Primary care, 3 providers, $3M EBITDA 4-6x $12M-$18M
The 5-Stage Owner Transition Timeline The 5-Stage Owner Transition Timeline From day-to-day operator to fully transitioned — typically 18-36 months Stage 1 Operator Owner = full-time in the business Month 0 Pre-prep state Stage 2 Documenter SOPs, financials, org chart built Month 6-12 Buyer-readiness Stage 3 Delegator Manager takes day-to-day ops Month 12-18 Owner-independent Stage 4 Closer LOI, diligence, close Month 18-24 Sale process Stage 5 Transitioned Consulting wind-down, earnout vesting Month 24-36 Post-close Skipping stages 2-3 is the #1 reason succession plans fail at the LOI stage
Illustrative timeline. Real durations vary by business size, owner involvement, and successor readiness. Owners who compress these stages typically lose 20-40% of valuation in the sale process.

Common medical practice sale mistakes

Five recurring mistakes destroy value in medical practice sales. Each is correctable with proper preparation.

  • Engaging non-healthcare M&A advisor. Generic M&A advisors don’t understand Stark Law, payor mix dynamics, or PE roll-up specialty mechanics. Use specialists.
  • Underestimating regulatory timeline. Medicare/state licensure can add 6-9 months. Plan accordingly.
  • Aggressive add-back schedule. Buyers and QoE providers heavily scrutinize physician compensation, RVU calculations, and ancillary income. Conservative add-backs win.
  • Not running competitive process. Bilateral negotiation with one PE platform typically produces 15-25% lower outcomes than running 3-5 competing platforms.
  • Ignoring post-close employment terms. Buyer’s standard employment contract may have restrictive non-competes, low base + production bonus, weak benefits. Negotiate carefully.

Independent practice vs PE platform: should I sell or stay?

Some physicians fight the PE consolidation trend and remain independent. The right answer depends on specialty, age, and personal priorities.

  • Sell to PE when: approaching retirement (5-10 years out), want partial liquidity + continued work, sector has active PE consolidation, want larger group’s administrative support.
  • Stay independent when: mid-career physician (15+ years to retirement), enjoy operational control, sector has limited PE activity, willing to accept administrative burden.
  • Wait and see: 5-10 year horizon, monitor specialty consolidation, optimize practice for eventual sale, maintain optionality.

Conclusion

Selling a medical practice in 2026 produces 4-12x EBITDA depending on specialty. PE-backed physician groups dominate the active consolidation specialties (dermatology, ophthalmology, GI, dental, vet); hospital systems and larger practices acquire in less-consolidated specialties (primary care, cardiology, OB/GYN). Regulatory complexity adds 6-12 months to the timeline; preparation 12+ months in advance produces 20-40% higher proceeds. CT Acquisitions works with PE-backed physician groups — the buyer pays our fee at close.

Frequently Asked Questions

How much is a medical practice worth?

Depends on specialty and PE consolidation activity. 2026 typical multiples: dermatology 8-12x EBITDA, ophthalmology 8-11x, GI 7-10x, orthopedics 7-10x, dental 6-9x, primary care 4-6x, vet 8-15x. For a 3-provider specialty practice at $3M EBITDA, that’s $12M-$36M enterprise value depending on specialty and quality factors.

Who buys medical practices?

Three primary buyer types: (1) PE-backed physician groups — most active in dermatology, ophthalmology, GI, dental, vet, ortho, plastic surgery; pay highest multiples (8-12x). (2) Hospital systems — acquire for service-line expansion and referral capture; pay 3-6x. (3) Larger practices/groups — acquire for geographic expansion and ancillary revenue; pay 4-7x.

How long does it take to sell a medical practice?

9-18 months from advisor engagement to close, longer than standard M&A due to regulatory complexity. Stages: 6-9 months preparation + 2-3 months marketing/LOI + 4-6 months due diligence + regulatory transfer (state licensure, Medicare provider agreement, malpractice tail). Plan 12+ months for serious preparation work pre-engagement.

What is Stark Law and how does it affect practice sales?

Stark Law prohibits physicians from referring Medicare/Medicaid patients to entities with which they have a financial relationship (with safe harbor exceptions). Affects sale structures: earnouts tied to referrals, post-close compensation structures, joint ventures with hospitals all need Stark compliance review. Healthcare M&A counsel essential for navigating.

What’s the difference between PE-backed and hospital acquisition?

PE-backed group: physician becomes W-2 employee + holds platform equity (10-20%); typical 8-12x EBITDA valuation; aggressive consolidation strategy; physician retains operational input. Hospital system: physician becomes hospital employee; typical 3-6x EBITDA valuation; loses owner autonomy and equity upside; focus on service-line integration and referral capture.

What is a DSO (Dental Service Organization)?

A DSO is a management services organization that provides non-clinical management to dental practices (administration, marketing, finance, HR, IT, supply chain) in exchange for management fees. PE-backed DSOs acquire equity in clinical practices (often via Management Services Agreement structures in restricted states). Major DSOs: Heartland Dental ($2B+ revenue), Aspen Dental, Pacific Dental Services, Smile Brands. Multiples: 6-9x EBITDA typical.

Do I have to stay after selling my practice to PE?

Typically yes, 3-5+ years as W-2 employee with production-based compensation. PE platforms require physician continuity to retain patients and referrals. Employment contracts typically include: base salary + production bonus, equity vesting (10-20% platform equity, 4-5 year vest), restrictive covenants (non-compete, non-solicitation), and right of first refusal on subsequent practice equity transactions.

What is malpractice tail coverage?

Tail coverage extends malpractice insurance to cover claims arising from pre-close clinical activities that may be filed after the sale closes. Required because most claims-made policies stop covering past activities once premium payments end. Cost: $25K-$200K depending on specialty, claim history, and policy structure. Usually negotiated as buyer-paid or split-cost in the LOI.

How can I maximize my practice’s valuation?

Six levers: (1) optimize payor mix (60%+ commercial), (2) increase provider productivity above specialty median, (3) document inbound referral patterns systematically, (4) add ancillary revenue (in-office surgery, imaging, lab, infusion), (5) own practice real estate (sell-leaseback adds value), (6) build provider depth (3+ providers reduces key-person risk; 5+ attracts PE platforms). Each lever moves multiples 0.5-1.5x within specialty range.

Should I sell my real estate with my practice?

Usually no, sell separately. Real estate-physician separation produces: (1) sale-leaseback structure where physician retains real estate ownership + receives lease income, (2) potential 10-15% additional cap-rate-based value, (3) cleaner buyer diligence (buyer focused on practice operations, not real estate). Common structure: practice sells at EBITDA multiple; real estate sells at separate cap rate.

What’s the difference between MSO and practice acquisition?

Practice acquisition: PE platform acquires clinical practice equity directly; physician becomes employee + platform equity holder. MSO (Management Services Organization) structure: physician retains clinical practice ownership but contracts with MSO for management services; MSO can hold equity in non-clinical practice operations. Used in states (CA, NY, NJ, TX) with corporate practice of medicine restrictions limiting non-physician practice ownership.

Why work with CT Acquisitions to sell my practice?

CT Acquisitions works with PE-backed physician groups actively acquiring practices across consolidation-active specialties. We can match your practice to the specific PE platforms most likely to fit your specialty, geography, and size. The buyer pays our fee at close — the seller pays nothing. No exclusivity, no contracts. Most engagements close in 9-15 months given medical regulatory timelines.

Related Guide: Private Equity Roll-Up Strategy — PE consolidation playbook

Related Guide: Exit Strategy for a Small Business — All 7 exit paths compared

Related Guide: Family Office vs Private Equity — Buyer-type comparison

Related Guide: 2026 Dental DSO PE Roll-Up Tracker — Active dental platforms mapped

Want a Specific Read on Your Business?

30 minutes, confidential, no contract, no cost. You leave with a read on your local buyer market and a likely valuation range.

CT Acquisitions is a trade name of CT Strategic Partners LLC, headquartered in Sheridan, Wyoming.
30 N Gould St, Ste N, Sheridan, WY 82801, USA · (307) 487-7149 · Contact






Christoph Totter, Founder of CT Acquisitions

About the Author

Christoph Totter is the founder of CT Acquisitions, a buy-side M&A advisory firm in Sheridan, Wyoming. He is a published researcher in lower middle market M&A on Zenodo, Academia.edu, and ORCID, and an active contributor on LinkedIn on M&A, private equity, and business sales. CT Acquisitions works directly with 100+ buyers including PE platforms, family offices, search funders, and strategic consolidators. Buyers pay our fee, never sellers. No retainer, no exclusivity, no contract until close.

Leave a Reply

Your email address will not be published. Required fields are marked *